Nemaura Medical

Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14th Annual LD Micro Main Event Conference.

Nemaura Medical to Present at the LD Micro Main Event Conference

MiBoKo , a noninvasive glucose sensor utilizing AI mobile application, addresses a substantia l multibillion-dollar market opportunity in healthcare

Nemaura Medical Launches Beta Version of Its Metabolic Health Program

The stock price of Nemaura Medical, Inc. (NASDAQ: NMRD) increased by over 4% today. This is why it happened.

NMRD Stock: Why It Increased Today

Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up

Nemaura Medical Announces Commercial Agreement with UK Licensee

NEW YORK, Sept. 24, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- Nemaura Medical Inc. (NASDAQ: NMRD)  announces the availability of a broadcast titled, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity.”

Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

Loughborough, England, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that Dr. Osama Hamdy, MD, PhD, has joined their advisory board as consultant, and is expected to partake on and advise on Key Opinion leader studies in both the Diabetes field and Metabolic Health field using Nemaura's glucose monitoring technology in the near future.

Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board

Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022.

Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021

Loughborough, England, July 12, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021.

Nemaura Medical to Present at the Access to Giving Virtual Investor Conference on July 13, 2021

Nemaura is an intriguing company developing a wearable patch for monitoring of glucose & blood sugar levels by Type-2 and pre-diabetes patients.

Nemaura: Wearable Monitoring Patches For Type-2 Diabetics Could Be An Inspired Move

Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces a presentation referring to its licensed Why WAIT® program at the American Diabetes Association's 81st Annual Scientific Sessions.

Nemaura Medical Announces Presentation on its Licensed Why WAIT Program During the American Diabetes Association 81st Annual Scientific Sessions

Loughborough, England, June 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT™diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and released financial results for the fiscal year ended March 31, 2021.

Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2021

For millions of diabetic patients worldwide, the reality of constantly having needles pricked into the body for glucose monitoring can be a never-ending nightmare. With over 460 million people currently suffering from diabetes and the number of pre-diabetes cases at almost 3 times this number, diabetes is an urgent global health crisis that companies like Nemaura Medical, Inc. (NASDAQ:  NMRD ), are working around the clock to manage and reverse.

Nemaura Medical Makes Progress with Advanced Noninvasive Sensors for Diabetes Management and Metabolic Health

Loughborough, England, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

Nemaura Medical to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Loughborough, England, May 26, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.

Neumaura Medical, Inc. to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

The stock price of Nemaura Medical Inc (NASDAQ: NMRD) increased by 140.69% this past month. This is why it happened.

Nemaura Medical (NMRD) Stock: 140.69% Increase This Past Month Explanation

GT Biopharma Inc

Ocugen, Inc.

These penny stocks hit it out of the park in 2021 & continue to climb in May. The post Former Penny Stocks To Watch Making Their Mark In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Former Penny Stocks To Watch Making Their Mark In 2021

Shares of Nemaura Medical Inc. (NASDAQ:NMRD) may be about to drop even more than they have so far today. On Wednesday, the bulls were firmly in control.

Nemaura Medical Stages Epic Reversal

The stock price of Nemaura Medical Inc (NASDAQ: NMRD) increased 12.57% (from $11.06 to $12.58) pre-market. This is why it happened.

NMRD Stock: 12.57% Increase (From $11.06 To $12.58) Pre-Market Explanation

Nemaura Medical Inc. (NASDAQ: NMRD) shares are trading higher after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethitronix Ltd. The company also announced there is an additional rolling monthly purchase order forecast for the next 24 months of 15,000 transmitters and 2.1 million sensors, with an option to increase volumes based on customer response.

Why Nemaura Medical's Stock Surged 135% Today

The stock price of Nemaura Medical Inc (NASDAQ: NMRD) increased from $4.70 to a day high of $8.20 during intraday trading. This is why it happened.

NMRD Stock: From $4.70 To $8.20 (74.46% Increase) Intraday Explanation

iBio

Cocrystal Pharma

Nemaura Medical Inc. (NASDAQ: NMRD), iBio, Inc. (NYSE: IBIO) and Cocrystal Pharma, Inc. (NASDAQ: COCP) are among the healthcare movers Wednesday. Nemaura Rallies On Receipt of Orders: Nemaura, a medtech company developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced the receipt of purchase orders for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee DB Ethitronix.

Why Nemaura, iBio And Cocrystal Are Moving Wednesday

Loughborough, England, April 29, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today issues a Letter To Shareholders from CEO Dr. Faz Chowdhury summarizing its Shareholder Update call held yesterday, April 28, 2021. This letter is to help clarify the content from the call in which there may have been intermittent audio issues.

Nemaura Medical Issues Letter to Shareholders Following April 28 Shareholder Update Call

Loughborough, England, April 21, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET.

Nemaura Medical to Conduct Shareholder Update Call April 28, 2021, 4:30PM ET

Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Samantha Sanders as its Global Head of Digital Programs.

Nemaura Medical Appoints Samantha Sanders as Global Head of Digital Programs

Loughborough, England, March 25, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it has retained Paul Kennedy who will be advising the Company on its commercial growth initiatives.

News for Nemaura Medical Stock (NMRD)